CoChat

Omalizumab mitigates anaphylaxis during ultrarush honey bee venom immunotherapy in monoclonal mast cell activation syndrome

da Silva, Elizabeth Nicole, Randall, Katrina Louise · 2013 · The Journal of Allergy and Clinical Immunology: In Practice
Cited by 45

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Venom immunotherapy (VIT) is indicated for all individuals with sting-induced anaphylaxis and evidence of venom-specific IgE. For patients with a concurrent proliferative mast cell disorder, such as monoclonal mast cell activation syndrome (MMAS) or mastocytosis, which confer increased risk of venom allergy, life-long VIT has been recommended on the basis of case reports that describe fatal anaphylaxis due to field stings after discontinuation of VIT. Elevated baseline serum tryptase in the setting of sting-induced anaphylaxis, including but not exclusively in mastocytosis, confers an increased risk of anaphylaxis during VIT. Several case reports have indicated the efficacy of omalizumab, a humanized monoclonal IgG1 anti-IgE Fce antibody in mitigating the risk of anaphylaxis in high-risk settings during VIT. This has been demonstrated by using both pretreatment and maintenance omalizumab dosing to treat patients at high risk without mastocytosis who were receiving modified rush or ultrarush VIT, and both during initiation of modified rush and as high-dose monthly therapy during maintenance VIT in individuals with mastocytosis. However, not all case reports support the efficacy of omalizumab during immunotherapy, and it remains unclear as to what other factors, apart from the kind of protocol used and the presence or absence of monoclonal mast cell disorders contribute to clinical success. An accepted mechanism of action is via downregulation of FceRI in response to depletion of circulating IgE, thereby reducing mast cell responsiveness. However, a clinical report that described the efficacy of omalizumab in sting-induced anaphylaxis in a patient with mastocytosis but without demonstrable venom-specific IgE suggests that, despite the lack of cellular evidence, an additional mechanism of action, such as mast cell apoptosis via reduced IgE binding with subsequent reduction in mast cell burden, cannot be discounted. We describe a case of omalizumab used to mitigate anaphylaxis during ultrarush honey bee VIT in a patient with MMAS. This case is unique in that the target dose of 100 mg was safely attained within 3 days, with maintenance doses continued safely thereafter for more than 12 months to date, even after omalizumab therapy had been stopped.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jaip.2013.07.004

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 45

Metadata

Authors
da Silva, E. N., & Randall, K. L.
Venue
The Journal of Allergy and Clinical Immunology: In Practice
Publisher
Elsevier BV
Published
2013-11
Volume
1
Issue
6
Pages
687-688
ISSN
2213-2198 (ISSN-L)
OpenAlex
W2081196283
Cited by
45
References
3
FWCI
2.23
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Omalizumab mitigates anaphylaxis during ultrarush honey bee venom immunotherapy in monoclonal mast cell activation syndrome. https://app.cochat.ai/papers/10.1016/j.jaip.2013.07.004
The paper
da Silva, E. N., & Randall, K. L. (2013). Omalizumab mitigates anaphylaxis during ultrarush honey bee venom immunotherapy in monoclonal mast cell activation syndrome. The Journal of Allergy and Clinical Immunology: In Practice. https://doi.org/10.1016/j.jaip.2013.07.004

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.